BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 7973772)

  • 1. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
    Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
    Crawford J; O'Rourke MA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: vinorelbine (navelbine) in non-small cell lung cancer.
    Crawford J
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer.
    Drinkard LC; Hoffman PC; Samuels BL; Watson S; Bitran JD; Golomb HM; Vokes EE
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):30-7; discussion 41-4. PubMed ID: 7537911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
    Coltman CA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.
    Vokes EE; Rosenberg R; Jahanzeb M; Craig J; Gralla R; Belani C; Jones S; Bigley J; Hohneker J
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):35-8; discussion 38-41. PubMed ID: 7973767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.
    Chang AY; DeVore R; Johnson D
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):19-21. PubMed ID: 8610231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.
    Viallet J; Ayoub J; Rousseau P; Souhami L; Hohneker J; Shepherd F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):64-71; discussion 71-2. PubMed ID: 7973771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
    Crawford J
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):85-8. PubMed ID: 7526468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer.
    Chang AY; Garrow GC
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):66-70; discussion 70-1. PubMed ID: 7740336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.